Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0003 0.00 (0.00%)
As of 08/21/2026 02:27 PM Eastern
Compare

EFTR vs. ADTX, CMRA, SYRS, EVLO, and PXMD

Should you buy eFFECTOR Therapeutics stock or one of its competitors? eFFECTOR Therapeutics's main competitors and comparable companies include Aditxt (ADTX), Comera Life Sciences (CMRA), Syros Pharmaceuticals (SYRS), Evelo Biosciences (EVLO), and PaxMedica (PXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does eFFECTOR Therapeutics compare to Aditxt?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

In the previous week, Aditxt had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for eFFECTOR Therapeutics. Aditxt's average media sentiment score of 1.05 beat eFFECTOR Therapeutics' score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Aditxt Positive

eFFECTOR Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. eFFECTOR Therapeutics' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

eFFECTOR Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

eFFECTOR Therapeutics has higher earnings, but lower revenue than Aditxt. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Aditxt$14.34K0.48-$41.71M-$100.79 thousandN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
eFFECTOR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

eFFECTOR Therapeutics beats Aditxt on 8 of the 13 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Comera Life Sciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Comera Life Sciences Neutral

eFFECTOR Therapeutics has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Comera Life Sciences has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Summary

Comera Life Sciences beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
eFFECTOR Therapeutics Neutral

eFFECTOR Therapeutics has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

eFFECTOR Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
eFFECTOR Therapeutics N/A N/A N/A

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

Summary

eFFECTOR Therapeutics beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
eFFECTOR Therapeutics Neutral

Evelo Biosciences has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

eFFECTOR Therapeutics beats Evelo Biosciences on 5 of the 6 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

eFFECTOR Therapeutics' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
eFFECTOR Therapeutics N/A N/A N/A

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
eFFECTOR Therapeutics Neutral

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PaxMedica is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Summary

eFFECTOR Therapeutics beats PaxMedica on 6 of the 8 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.54B$7.36B$12.81B
Dividend YieldN/A2.62%2.54%10.78%
P/E Ratio0.00780.43270.5924.05
Price / SalesN/A758.13643.38104.95
Price / CashN/A15.4729.0336.89
Price / Book0.0010.4611.096.40
Net Income-$35.81M$2.79B$3.46B$347.95M
7 Day PerformanceN/A1.84%1.73%1.48%
1 Month PerformanceN/A4.73%7.34%5.13%
1 Year PerformanceN/A7.74%26.13%17.00%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A+50.0%$1KN/AN/A10
ADTX
Aditxt
0.4776 of 5 stars		$0.01
+127.3%		N/A-100.0%$4K$14.34KN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
SYRS
Syros Pharmaceuticals
N/A$0.00
-75.0%		N/A-99.5%$3K$386KN/A120
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel